Highlights

• Advanced Enzymes shares climbed over 13% and touched a fresh 52-week high.
• Q4 FY26 consolidated revenue increased 22% year-on-year to INR 2,034 million.
• Domestic sales rose 51% during the quarter, contributing over half of revenue.

Shares of Advanced Enzyme Technologies Limited (NSE:ADVENZYMES) gained sharply during Monday’s trading session after the company announced its fourth-quarter and full-year FY26 financial results. The stock rose 12.23% to INR 400.95 and touched a new 52-week high of INR 414.40 on the NSE.

The stock opened at INR 378.00 against the previous close of INR 357.25. During the session, the company recorded traded volume of 9.10 lakh shares with traded value of INR 36.40 crore. The company’s market capitalisation stood at approximately INR 4,558.22 crore.

Source: TradingView

Revenue And Profit Show Year-On-Year Growth

Advanced Enzymes reported consolidated revenue from operations of INR 2,034 million in Q4 FY26, compared with INR 1,672 million in Q4 FY25, reflecting 22% year-on-year growth.

EBITDA for the quarter stood at INR 632 million against INR 456 million in the corresponding quarter last year, while EBITDA margin improved to 31% from 27%.

Profit after tax increased 69% year-on-year to INR 453 million in Q4 FY26 from INR 267 million reported a year earlier. Earnings per share for the quarter stood at INR 3.84 compared with INR 2.37 in Q4 FY25.

For the full financial year FY26, consolidated revenue increased 17% to INR 7,458 million, while annual profit after tax rose 30% to INR 1,736 million.

Human Nutrition Segment Drives Quarterly Revenue

The Human Nutrition segment remained the largest contributor to quarterly revenue. Segment revenue increased 24% year-on-year to INR 1,281 million in Q4 FY26 from INR 1,031 million in Q4 FY25.

The company stated that the increase was supported by higher activities in Pharma/API and Bio-catalysis businesses.

Animal Nutrition revenue rose 19% to INR 250 million, while Bio-Processing revenue increased 17% to INR 324 million during the quarter. Specialized Manufacturing revenue also increased 17% to INR 180 million.

Domestic Business Contribution Increases

Domestic sales rose significantly during the quarter. Revenue from India stood at INR 1,061 million in Q4 FY26 compared with INR 704 million in Q4 FY25, representing 51% growth.

International revenue remained relatively stable at INR 973 million. The company reported lower revenue from the Americas and Europe, while Asia excluding India and other international markets recorded growth.

Domestic sales accounted for 52% of quarterly revenue compared with 42% in the corresponding period last year.

Source: company filing

FY27 Outlook Focuses On Nutrition And Probiotics

The company said it remains focused on Human Nutrition, Animal Nutrition and Bio-Processing businesses during FY27. It also highlighted continued investments in probiotics, bio-catalysis applications and research infrastructure.

Advanced Enzymes additionally stated that it is expanding its B2C nutraceutical business in India under the “Wellfa” brand while continuing to explore inorganic growth opportunities funded through internal accruals.

Key Risks

• International revenue growth remained limited during the reported quarter.
• Revenue from Europe and Americas declined on a year-on-year basis.
• Bio-Processing segment recorded sequential decline during Q4 FY26.
• Stock volatility increased after touching fresh 52-week high levels.

Summary

Advanced Enzyme Technologies (NSE:ADVENZYMES) shares surged after the company reported higher quarterly revenue, profit and margins for Q4 FY26. Domestic business growth supported overall performance, while Human Nutrition remained the largest revenue contributor.

The company also highlighted expansion plans across probiotics, bio-catalysis and nutraceutical segments. However, some international markets reported weaker revenue trends during the quarter despite overall annual growth.

FAQs

Q: Why did Advanced Enzymes shares rise on May 11, 2026?
A: The stock gained after the company reported higher quarterly revenue, profit growth and improved operating margins.

Q: What was Advanced Enzymes’ Q4 FY26 revenue?
A: The company reported consolidated revenue of INR 2,034 million during the fourth quarter of FY26.

Q: Which segment contributed most to quarterly revenue growth?
A: Human Nutrition remained the largest segment contributor with 24% year-on-year revenue growth.